Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EXP 2528

Known as: EXP-2528, EXP2528 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Protective Effect of Compound EXP-2528 on Brain Ischemia-Reperfusion Injury in Rats
OBJECTIVE To investigate the protective effect and preliminary mechanism of compound EXP-2528,a novel AT1 receptor antagonist,on… Expand
2007
2007
Effect of compound EXP-2528 on angiotensin II-induced E-selectin and VCAM-1 expression in rat brain microvascular endothelial cells in vitro.
The aim of this study is to investigate the effect and mechanism of angiotensin (Ang) II on E-selectin and vascular cell adhesion… Expand
2006
2006
Angiotensin II stimulates intercellular adhesion molecule-1 via an AT1 receptor/nuclear factor-kappaB pathway in brain microvascular endothelial cells.
Microvascular changes in the brain are significant causes of cerebral edema and ischemia injury. A number of studies suggest that… Expand
2005
2005
P-448: EXP-2528, a novel angiotensin II type 1 receptor antagonist, protects cerebral microvascular endothelial cells against Angiotensin II injury by antioxidant role
 
2005
2005
P-447: EXP-2528, a novel angiotensin II type 1 receptor antagonist, protects the brain after transient focal ischemia
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE